Shanghai Fosun Pharmaceutical To Enter China's Injectable Market
This article was originally published in PharmAsia News
Executive Summary
Shanghai Fosun Pharmaceutical recently revealed that its two wholly-owned subsidiaries, Fosun International and Fosun Industrial, signed an agreement to buy from Beijing Hexin Boye Consultancy and Aleph Biomedical the totaling stake of 75 percent in Aleph Biomedical, allegedly at RMB 660 and 9 million
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.